BIVI:NSD-BioVie Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.10

Change

-0.38 (-2.62)%

Market Cap

USD 0.32B

Volume

6.40K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+39.90 (+11.51%)

USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.60 (+3.41%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+9.38 (+1.63%)

USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

+1.73 (+0.87%)

USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+1.09 (+2.41%)

USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+14.03 (+4.29%)

USD29.25B N/A N/A
SGEN Seagen Inc

+3.95 (+2.56%)

USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

+0.47 (+1.26%)

USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

+0.85 (+0.48%)

USD21.03B N/A N/A

ETFs Containing BIVI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.59% 44% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.59% 44% F 19% F
Trailing 12 Months  
Capital Gain -6.00% 54% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.00% 54% F 19% F
Trailing 5 Years  
Capital Gain 11,650.00% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 11,650.00% 99% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain 3,265.20% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3,265.20% 100% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 6,729.03% 1% F 1% F
Risk Adjusted Return 48.52% 74% C 67% D+
Market Capitalization 0.32B 50% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 27.70 6% F 4% F
Price / Cash Flow Ratio -193.95 98% A+ 93% A
EV/EBITDA 16.21 27% F 50% F
Management Effectiveness  
Return on Equity -394.61% 5% F 12% F
Return on Invested Capital 29.18% 92% A- 94% A
Return on Assets -57.79% 9% F 3% F
Debt to Equity Ratio -0.29% 87% B+ 92% A-
Technical Ratios  
Short Ratio 8.99 17% F 9% F
Short Percent 15.20% 11% F 11% F
Beta 2.04 18% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector